Shanghai Pharmaceuticals: Omeprazole Sodium Bicarbonate Dry Suspended Powder Approved for Production

Shanghai Pharmaceuticals announced that its subsidiary, Shanghai Pharmaceuticals Xin Yi, has received the "Drug Registration Certificate" for Omeprazole Sodium Bicarbonate Dry Suspension issued by the National Medical Products Administration, and the drug has been approved for production. The specifications of this drug are 20mg of Omeprazole and 1680mg of Sodium Bicarbonate per sachet, with a registration classification of Class 3 chemical drugs, primarily used for the short-term treatment of active duodenal ulcers and gastroesophageal reflux disease. As of the date of this announcement, the company has invested approximately RMB 5.9355 million in research and development for this drug. The amount spent on the procurement of this drug by hospitals in mainland China is projected to be RMB 15.69 million in 2025.